American Diabetes Association’s (ADA’s) 77th Scientific Sessions held in San Diego, California, US. During that session, a seminar was given regarding the overtreatment of type 2 diabetes (T2D).
T2D is a chronic disease. In which, the way the body uses glucose is changed and this remains without a cure. In other words, your body does not process insulin properly, called insulin resistance. At first, the duct gland makes extra insulin to make up for it. Over time your duct gland isn’t able to keep up and can’t make sufficient insulin maintain your blood glucose levels normal.
While there is no known cure for type 2 diabetes, but various drug options for the treating Type 2 Diabetes do exist, from injections to tablets. According to physicians survey conducted by GlobalData , the highly prescribed drug include glucagon-like peptide-1 receptor agonists, biguanides, thiazolidinediones, sulfonylureas, sodium-glucose cotransporter -2 inhibitors and dipeptidyl peptidase-4 inhibitors.
Session bestowers agreed that even though the thrust for a additional personalized approach to diabetes treatment as per ADA guidelines, the lack of coarseness has resulted in various cases of overtreating the T2D patients. As a result, patients are probable to exhibit less consent, experience side effects, and be faced with higher costs. Side effects can be brutal, such as with hypoglycemia for the patients on insulin therapy.
To fight overtreatment, presenters recommended that instead of offering aggressive treatment to all T2D patients, it should be kept for high-risk T2D patients who would get the most benefit. Also, glycated hemoglobin aims should be less strict in older T2D patients, as non-glycemic benefits may take 10 or more years to be recognized.
In spite of the variety of drugs available for T2D patients, betterments in the managing treatment of the disease are guaranteed. More specific diabetes phenotyping, genetic studiesand results from large relative treatment studies, are expected to decreased overtreatment cases. One such study is GRADE, which is supported by the National Institute of Diabetes and Digestive and Kidney Diseases. The study is being conducted over patients, those prescribed with T2D drugs for a period of seven years, and the glycemic results are expected in 2021. Thus, even though the ADA guidelines are a handy framework for personalized disease management, alterations will need to be integrated to better replicate current and future verification for personalized treatment management.